167 related articles for article (PubMed ID: 26944437)
21. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Clin Oncol; 2001 Apr; 19(7):1901-5. PubMed ID: 11283121
[TBL] [Abstract][Full Text] [Related]
22. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
[TBL] [Abstract][Full Text] [Related]
23. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
International Collaborative Ovarian Neoplasm Group
Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
[TBL] [Abstract][Full Text] [Related]
26. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
27. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
28. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
Meerpohl HG
Praxis (Bern 1994); 1999 Mar; 88(12):513-8. PubMed ID: 10235026
[TBL] [Abstract][Full Text] [Related]
29. Epothilones in the treatment of ovarian cancer.
Diaz-Padilla I; Oza AM
Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study.
Kurtz JE; Deplanque G; Duclos B; Eichler F; Giron C; Limacher JM; Herbrecht R; Maloisel F; Oberling F; Bergerat JP; Dufour P
Gynecol Oncol; 1998 Sep; 70(3):414-7. PubMed ID: 9790797
[TBL] [Abstract][Full Text] [Related]
31. Pro-apoptotic activity of new analog of anthracyclines--WP 631 in advanced ovarian cancer cell line.
Gajek A; Denel M; Bukowska B; Rogalska A; Marczak A
Toxicol In Vitro; 2014 Mar; 28(2):273-81. PubMed ID: 24287111
[TBL] [Abstract][Full Text] [Related]
32. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
33. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
35. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
[TBL] [Abstract][Full Text] [Related]
36. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Simpkins F; Belinson JL; Rose PG
Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
[TBL] [Abstract][Full Text] [Related]
37. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
Ozols RF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
[TBL] [Abstract][Full Text] [Related]
38. [First line chemotherapy for advanced ovarian cancer in 2000: standards and questions].
Cure H; Dauplat J; Cholet P
Bull Cancer; 2000 Feb; 87(2):189-99. PubMed ID: 10705290
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy of advanced ovarian cancer.
McGuire WP; Ozols RF
Semin Oncol; 1998 Jun; 25(3):340-8. PubMed ID: 9633846
[TBL] [Abstract][Full Text] [Related]
40. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
Minagawa Y; Kigawa J; Kanamori Y; Itamochi H; Terakawa N; Okada M; Kitada F
Gynecol Oncol; 2006 Jun; 101(3):495-8. PubMed ID: 16375950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
